Refine by
Multiple Sclerosis Articles & Analysis
40 news found
Autoimmune Diseases: Antibodies are designed to modulate the immune response in conditions like rheumatoid arthritis and multiple sclerosis. 3. Infectious Diseases: Antibodies are developed against rapidly evolving pathogens, such as the influenza virus and SARS-CoV-2. ...
Moreover, without this support IVS would not have been able to attract multiple dynamic collaborations with key industry and academic partners that helped IVS create a rich and diverse product/assay and service portfolio that is designed towards unmet needs of drug discovery, development and patient populations with debilitating diseases. ...
Institut Guttmann (Badalona); Heidelberg University Hospital (Heidelberg), Asepeyo Hospital (Sant Cugat); CEN (European Center of Neurosciences) (Madrid); Vall d’Hebron Hospital (Barcelona); SIRN (Barcelona); Isidre Esteve Foundation (Sant Cugat); National Hospital for Paraplegics (Toledo); Association of Multiple Sclerosis and other neurological diseases ...
The two development programs include multiple studies examining use of zuranolone in several thousand people with a variety of dosing, clinical endpoints, and treatment paradigms. ...
Today, Biogen has a leading portfolio of medicines to treat multiple sclerosis, has introduced the first approved treatment for spinal muscular atrophy, and developed the first and only approved treatment to address a defining pathology of Alzheimer’s disease. ...
iBio is jockeying for position as a leading player in Al-powered drug discovery while also expanding its immuno-oncology pipeline after closing on the acquisition of multiple assets from its partner, RubrYc Therapeutics. The plant-based drug developer and contract development and manufacturing organization (CDMO) said the deal shores up its ambition to bring immunotherapies to ...
New Therapeutic Candidates: Three promising immuno-oncology candidates, plus a partnership-ready PD-1 agonist for serious autoimmune diseases, such as systemic lupus erythematosus and multiple sclerosis. Purchase terms include: An upfront payment of $1 million in iBio’s common stock to RubrYc investors. ...
The two development programs include multiple studies examining use of zuranolone in several thousand people with a variety of dosing, clinical endpoints, and treatment paradigms. ...
More than 50 health conditions are planned for Health Unmuted including diabetes, multiple sclerosis, breast cancer and gastrointestinal conditions. About Mission Based Media Ltd. ...
(Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today announced that a poster detailing the benefits of the Company’s Portable Neuromodulation Stimulator (“PoNS”) Therapy combined with a therapeutic exercise program was presented at the 2022 Consortium of Multiple Sclerosis ...
PoNS is indicated in the U.S. for use as a short-term treatment of gait deficit in adults with mild-to-moderate symptoms from multiple sclerosis (“MS”) and is available by prescription only. ...
(Nasdaq: HSDT) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today announced that an abstract highlighting real-world data, which shows the impact of translingual neurostimulation as a rehabilitation therapy to improve gait in people with multiple sclerosis (MS), has been selected for a poster ...
(TASE: KDST), a clinical stage cell therapy company developing a treatment for ALS and a potential cure for diabetes, is expanding its R&D activity with the exploration of developing a treatment for Multiple Sclerosis (MS). As part of this initiative, the company has signed a service agreement with Hadasit Medical Research Services and Development Ltd. ...
Inbrija further strengthens Biopas’ complete and innovative CNS portfolio now consisting of nine original treatments: for Parkinson’s disease, epilepsy, movement disorders, sialorrea, multiple sclerosis, anxiety, and sleep disorders,” said Pascal Forget, CEO of Biopas. ...
To prevent graft rejection, transplanted patients are treated with lifelong immunosuppressive therapy, which impacts the body’s immune system and is associated with multiple side effects, including an increased risk of severe life-threatening infections, malignancies, cardiovascular disease, and other drug-related toxicities, such as nephrotoxicity, which can impact the ...
The funds will be used to advance the filing of an IND with the FDA by the end of 2022, to secure the approval of the FDA of the anticipated Phase IIa, US, multicenter, clinical trial protocol of AstroRx® for the treatment of ALS and expand the use of AstroRx® cell product for other neurological conditions such as multiple sclerosis and glaucoma. ...
BOSTON, MA, February 14, 2022, PRNewswire – Qynapse Inc., a medical technology company commercializing an AI-powered neuroimaging software platform for central nervous system (CNS) disorders, is pleased to present 2 posters at the annual Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum 2022, on February 24-26, in West ...
ByQynapse
Millions of people rely on self-catheterization to empty their bladder due to conditions such as urinary bladder retention, spinal cord injury, traumatic brain injury, multiple sclerosis, and more. If you are an uncoated straight catheter user, a high-quality sterile catheter lubricant is an important addition to your catheter regimen to ensure a comfortable ...
“Acorda has two important products on the market, one for Parkinson’s disease and one for multiple sclerosis. I’m impressed by the progress they have made in 2021 in addressing the company’s challenges, and I look forward to helping build on this progress in 2022 and ...
Qynapse will demo its flagship FDA-cleared and CE-marked neuroimaging solution, QyScore®, which combines MRI scans and AI to produce rapid, actionable insights into CNS disorders, such as Alzheimer’s disease, multiple sclerosis and Parkinson’s disease. “This year’s event represents a turning point in our product evolution as we have ...
ByQynapse